Lonza Group Ltd is a corporation incorporated under the laws of Switzerland and
has been listed on the SIX Swiss Exchange (the “SIX”) since November 1999.
Lonza is a supplier to the pharmaceutical, healthcare and life sciences
industries with products and services spanning from research to final product
manufacture to meet customers’ needs. The products Lonza manufacture for the
life sciences industry can be characterised as very complex molecules which are
manufactured in a highly regulated environment and will end up in the body of
human beings or animals.
Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and
biotechnology industries. The Group has strong capabilities in large and small
molecules, peptides, amino acids and niche bioproducts which play an important
role in the development of novel medicines and healthcare products. The Group
provides cell-based research, endotoxin detection and cell therapy
manufacturing. The Group is also a provider of high value chemicals and biotech
ingredients to the nutrition, hygiene, preservation, agro and personal care
markets.
To provide optimal support to its customers, the Group is organized into three
business divisions, namely, Custom Manufacturing, Life Science Ingredients and
Bioscience, which focus on specific sets of customers and their needs.
SGX source · Source update: 07/01/2025 08:45:30 AM (timezone not specified). Source text may be historical.